A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
- Abciximab administration is safe and reduces ischemic complications in patients
undergoing rescue PCI after failed thrombolysis compared to placebo.
- Abciximab improves angiographic scores and ventricular function after rescue-PCI
compared to placebo.
- Intracoronary abciximab administration is more effective than intravenous route of
administration in terms of acute and mid-term angiographic and clinical results.
- Intracoronary and intravenous bolus administration of abciximab dose provides similar
platelet aggregation inhibition (PAI).
- There is a significant relationship between PAI after abciximab administration and
indexes of myocardial perfusion.
- Routine use of Sirolimus-eluting stents (Cypher, Cordis, US) in rescue-PCI is associated
with a low rate of target vessel revascularization.
- Cardiac MRI early and late after rescue-PCI provides detailed information on myocardial
injury and irreversible necrosis, which are correlated with angiographic perfusion
scores.
- After uncomplicated trans-radial rescue PCI, patients can be retransferred early to
their referring center.
Phase:
Phase 4
Details
Lead Sponsor:
Olivier F. Bertrand
Collaborators:
Cordis Corporation Eli Lilly and Company
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments